Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.

ABSTRACT:

Background

Src family kinases control multiple cancer cell properties including cell cycle progression, survival, and metastasis. Recent studies suggest that the Src inhibitor dasatinib blocks these critical cancer cell functions.

Methods

Because the molecular mechanism of action of dasatinib in breast cancers has not been investigated, we evaluated the effects of dasatinib as a single agent and in combination with the commonly used chemotherapeutic doxorubicin, on the proliferation, viability, and invasive capacity of breast cancer cells lines earlier categorised as dasatinib-sensitive (MDA-MB-231) and moderately resistant (MCF7 and T47D). We also tested the effects of these drugs on the actin cytoskeleton and associated signalling pathways.

Results

The cell lines te

SUBMITTER: Pichot CS 

PROVIDER: S-EPMC2713704 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature